CDC Open Call to Industry – Influenza A(H5) Diagnostic Test Development and Validation
Closed Special Notice Posted
- Solicitation number
- 75D301-24-CTI-00001
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 62151 Medical and Diagnostic Laboratories
- Place of performance
- Atlanta, Georgia 30322, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention (CDC) has issued a Special Notice to industry for the development and validation of an Influenza A(H5) diagnostic test. This open call is being conducted under the CDC's Other Transaction (OT) authority and will be assessed similarly to a Broad Agency Announcement or Commercial Solutions Opening, with solutions evaluated independently for technical merit.
The purpose of this Special Notice is to solicit innovative solutions from industry to meet the CDC's needs for an Influenza A(H5) diagnostic test. The CDC is seeking a Nucleic Acid Amplification Test (NAAT) kit that can detect and differentiate the H5 subtype from seasonal influenza. Interested parties must submit a 2-3 page concept paper by June 24, 2024, and may be invited to a follow-on oral presentation. The CDC intends to make one or more OT agreements, with the goal of completing the work between November 1 and December 31, 2024. The government will provide control materials, comparison assays, and licensing support, and is open to a follow-on manufacturing and/or distribution agreement.
Notice text
3 versions
Update #3 · Latest ·
The Centers for Disease Control and Prevention (CDC) is initiating an open call for innovative solutions to meet the CDC's diagnostic test development needs.
This open Call to Industry is considered to have high potential for one or more agreements that may be accomplished via CDC's Other Transaction (OT) authority pursuant to 42 USC 242c. As such, assessment activities conducted in furtherance of an award or awards are considered competitive in the same manner as a Broad Agency Announcement (BAA) or Commercial Solutions Opening (CSO), and solutions will be assessed independently of one another primarily for technical merit. The procedures outlined in this open call are considered by CDC to satisfy the reasonable effort to obtain competition.
Solution Providers shall submit concept papers via email to mcrow@cdc.gov no later than 11:59 PM Eastern on Wednesday, June 26th, 2024 in order to be considered for further evaluation. The government does not anticipate the ability to consider late concept paper submissions.
Solution Providers are instructed to contact ONLY the CDC Office of Acquisition Services point(s) of contact notated in this announcement. Refer to the attachment(s) to this announcement for full details and instructions.
06/24/2024 Amendment: A Q&A document is provided which contains the government's responses to questions received from potential solutions providers. The deadline for concept paper submission is extended until 11:59 PM Eastern on Wednesday, June 26th, 2024.
Update #2 ·
The Centers for Disease Control and Prevention (CDC) is initiating an open call for innovative solutions to meet the CDC's diagnostic test development needs.
This open Call to Industry is considered to have high potential for one or more agreements that may be accomplished via CDC's Other Transaction (OT) authority pursuant to 42 USC 242c. As such, assessment activities conducted in furtherance of an award or awards are considered competitive in the same manner as a Broad Agency Announcement (BAA) or Commercial Solutions Opening (CSO), and solutions will be assessed independently of one another primarily for technical merit. The procedures outlined in this open call are considered by CDC to satisfy the reasonable effort to obtain competition.
Solution Providers shall submit concept papers via email to mcrow@cdc.gov no later than 11:59 PM Eastern on Monday, June 24th, 2024 in order to be considered for further evaluation. The government does not anticipate the ability to consider late concept paper submissions.
Solution Providers are instructed to contact ONLY the CDC Office of Acquisition Services point(s) of contact notated in this announcement. Refer to the attachment(s) to this announcement for full details and instructions.
Update #1 ·
The Centers for Disease Control and Prevention (CDC) is initiating an open call for innovative solutions to meet the CDC's diagnostic test development needs.
This open Call to Industry is considered to have high potential for one or more agreements that may be accomplished via CDC's Other Transaction (OT) authority pursuant to 42 USC 242c. As such, assessment activities conducted in furtherance of an award or awards are considered competitive in the same manner as a Broad Agency Announcement (BAA) or Commercial Solutions Opening (CSO), and solutions will be assessed independently of one another primarily for technical merit. The procedures outlined in this open call are considered by CDC to satisfy the reasonable effort to obtain competition.
Solution Providers shall submit concept papers via email to mcrow@cdc.gov no later than 11:59 PM Eastern on Monday, June 24th, 2024 in order to be considered for further evaluation. The government does not anticipate the ability to consider late concept paper submissions.
Solution Provider are instructed to contact ONLY the CDC Office of Acquisition Services point(s) of contact notated in this announcement. Refer to the attachment(s) to this announcement for full details and instructions.
Files
| File | Type | Posted |
|---|---|---|
| Influenza A(H5) Call to Industry 75D301-24-CTI-00001 QA 06.24.2024.xlsx | XLSX spreadsheet | |
| Influenza A(H5) Call to Industry 75D301-24-CTI-00001.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity